IKS014 treatment for advanced solid tumors expressing HER2

A Phase 1 Dose Escalation Trial to Determine the Safety, Tolerance, Maximum Tolerated Dose, and Preliminary Antineoplastic Activity of IKS014, a HER2-Targeting Antibody Drug Conjugate (ADC), in Participants With Advanced HER2+ Solid Tumors

This study is testing a new treatment called IKS014 for people with advanced solid tumors that have HER2 to see how safe it is and if it can help shrink the tumors.

Quick facts

• Phase: Phase 1
• Study type: Interventional
• Enrollment: 165 (estimated)
• Ages: 18 Years and up
• Sex: All
• Sponsor: Iksuda Therapeutics Ltd. (Industry-sponsored)
• Drugs / interventions: chemotherapy, radiation
• Locations: 13 sites (Newport Beach, California and 12 other locations)
• Trial ID: NCT05872295 on ClinicalTrials.gov

What this trial studies

This clinical trial evaluates the safety, tolerability, and anti-tumor activity of IKS014, a HER2-targeting antibody-drug conjugate, in patients with advanced solid tumors. The study consists of two parts: a dose-escalation phase to determine the recommended phase 2 dose (RP2D) and a dose-expansion phase to further assess safety, pharmacokinetics, pharmacodynamics, and efficacy at the RP2D. Participants will be monitored for various health parameters to ensure eligibility and safety throughout the trial.

Who should consider this trial

Good fit: Ideal candidates include patients with HER2 positive solid tumors who have specific expression levels and have received prior treatment with a CDK4/6 inhibitor.

Not a fit: Patients with solid tumors that do not express HER2 or those who have not received prior standard therapies may not benefit from this study.

Why it matters

Potential benefit: If successful, this treatment could provide a new therapeutic option for patients with advanced HER2-positive solid tumors.

How similar studies have performed: Other studies targeting HER2 have shown promising results, indicating potential success for this approach.

Eligibility criteria

Key Inclusion Criteria:

* HER2 positive solid tumors with expression defined as IHC3+, IHC2+/ISH+, or low HER2 expression defined as IHC2+ (ISH-) or IHC1+ (ISH- /+ or untested).
* Participants with HR positive BC must have received prior treatment with a CDK4/6 inhibitor, in countries where this is standard therapy.
* Platelets ≥ 75,000 /mcL
* Hemoglobin ≥ 9.0 g/dL
* Absolute neutrophil count ≥ 1000/mcL
* No administration of granulocyte colony-stimulating factor (G-CSF) is allowed within 2 weeks prior to first study drug administration
* Creatinine clearance \> 45/mL/min (using the Cockcroft-Gault equation)
* Aspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase \[SGOT\])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase \[SGPT\]) ≤ 3 x institutional upper limit of normal (ULN) ≤ 5 x ULN if liver metastases present
* Total bilirubin ≤ 1.5 x ULN if no liver metastases or \< 3 x ULN with Gilbert's Syndrome or liver metastases at baseline
* Albumin \> 2.5 g/dL
* Prothrombin time or international normalized ratio (INR) and either partial thromboplastin time (PTT) or activated (a) PTT ≤ 1.5 x ULN, ≤ 3 x institutional ULN if anticoagulated.
* Must have adequate treatment washout period before trial treatment, defined as: Major surgery (≥ 4 weeks) and radiation therapy (≥ 3 weeks; in case of palliative radiation ≥ 2 weeks)
* Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1 (or equivalent Karnofsky PS)
* Part 2 Dose Expansion Cohorts May Include:

  1. Advanced or metastatic BC that is confirmed HER2-positive defined as IHC 3+ or IHC 2+ and evidence of HER2 amplification by ISH, as per ASCO-CAP and previously treated with at least two HER2 directed treatments.
  2. Advanced or metastatic BC that has low HER2 expression defined as IHC2+ (ISH-) or IHC1+ (ISH-/+ or untested) and previously treated with at least 1 prior line of therapy which may include chemotherapy and/or a HER2 directed ADC.
  3. Advanced or metastatic GC or GEJ cancer that is confirmed HER2-positive defined as IHC 3+ or IHC 2+ and evidence of HER2 amplification by ISH as per ASCO-CAP and previously treated with at least 1 prior line of therapy, which may include chemotherapy and/or a HER2 directed ADC.
  4. Advanced or metastatic solid tumor that has been treated with standard of care therapy and is HER2 positive (HER2 IHC3+) as per ASCO-CAP or metastatic NSCLC (that has been treated with standard of care therapy) with a known activating HER2 (ERBB2) mutation.
  5. Advanced or metastatic adenocarcinoma of the Esophagus that has been treated with at least one prior line of standard treatment, which may have included a HER2-directed therapy. The tumor must be HER2 positive defined either HER2 IHC3+ or HER2 IHC 2+/ISH+.

Key Exclusion Criteria:

* History of (noninfectious) ILD/pneumonitis that required steroids, has current ILD/pneumonitis, or where suspected ILD/pneumonitis cannot be ruled out by imaging at Screening.
* Any clinically apparent ≥ Grade 2 pulmonary compromise resulting from intercurrent pulmonary illnesses including, but not limited to, any underlying pulmonary disorder (i.e., pulmonary emboli within three months of the trial enrollment, severe asthma, severe chronic obstructive pulmonary disease \[COPD\], restrictive lung disease, pleural effusion, etc.), and any autoimmune, connective tissue or inflammatory disorders with potential pulmonary involvement (e.g., rheumatoid arthritis, Sjogren's, sarcoidosis), or prior pneumonectomy.
* Current evidence of ≥ Grade 2 keratitis or other corneal abnormality.
* Evidence of a clinically significant (≥ Grade 2) abnormality on slit-lamp examination or other clinically significant ophthalmologic finding, as determined by an ophthalmologist.
* Evidence of clinically significant (≥ Grade 2) confluent superficial keratitis, a corneal epithelial defect, a corneal ulcer, or stromal opacity.
* Participant must not use contact lenses while participating in this study.
* Central nervous system metastatic disease unless treated with definitive local therapy (surgical resection, stereotactic radiotherapy, or whole brain radiotherapy) and participant is clinically, radiologically and neurologically stable for at least 4 weeks prior to the first dose of study drug not on steroid therapy or are on a stable or decreasing dose of steroids for at least 7 days prior to first dose of study drug. Prophylactic anticonvulsant medications are allowed.
* Active second malignancy or history of another malignancy within the last 2 years with the exception of:

  * Treated, non-melanoma skin cancers
  * Treated carcinoma in situ (CIS) (e.g., breast, cervix)
  * Controlled, superficial carcinoma of the urinary bladder
  * T1a or b carcinoma of the prostate treated according to local standard of care, with prostate specific antigen (PSA) within normal limits (WNL) for the institution
  * Papillary thyroid carcinoma Stage I treated surgically for cure
* Clinically significant cardiovascular disease or condition
* Clinically significant liver disease
* Any other serious/active/uncontrolled infection, any infection requiring parenteral antibiotics, or unexplained fever \> 38ºC within 2 weeks prior to first trial drug administration.
* Any other serious, life-threatening, or unstable preexisting medical condition (aside from the underlying malignancy), including significant organ system dysfunction, or clinically significant laboratory abnormality(ies), which, in the opinion of the Investigator, would either compromise the participant's safety or interfere with obtaining informed consent, compliance with trial procedures, or evaluation of the safety of the trial drug.

Where this trial is running

Newport Beach, California and 12 other locations

• Hoag Memorial Hospital Presbyterian — Newport Beach, California, United States (Recruiting)
• Dana Farber Cancer Institute — Boston, Massachusetts, United States (Recruiting)
• Tennessee Oncology — Nashville, Tennessee, United States (Recruiting)
• START Dallas - Fort Worth — Fort Worth, Texas, United States (Recruiting)
• Concord Repatriation General Hospital Medical Oncology Clinical Trials Unit — Concord, New South Wales, Australia (Recruiting)
• Macquarie University — Sydney, New South Wales, Australia (Recruiting)
• Westmead Hospital — Westmead, New South Wales, Australia (Recruiting)
• Peninsula & South Eastern Haematology and Oncology Group (PSEHOG) — Frankston, Victoria, Australia (Recruiting)
• Alfred Health — Melbourne, Victoria, Australia (Recruiting)
• Linear Clinical Research — Nedlands, Western Australia, Australia (Recruiting)
• Auckland City Hospital — Auckland, New Zealand (Recruiting)
• National Cancer Centre Singapore — Singapore, Singapore (Recruiting)
• Tan Tock Seng Hospital — Singapore, Singapore (Recruiting)

Study contacts

• Study coordinator: David Browning

Conditions Breast Cancer; Gastric Cancer; Gastroesophageal-junction Cancer; HER2; IKS014; Low HER2; Advanced tumors; HER2+